Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05072288

A Remote Physical Activity Program in the Population Suffering from Type 1 Myotonic Dystrophy

A Remote Physical Activity Program Via the PACE Tool to Counter the Physical Impairments, Accentuated by the Pandemic, in the Population Suffering from Type 1 Myotonic Dystrophy

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Université du Québec à Chicoutimi · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The COVID-19 pandemic exacerbates health problems by reducing access to adapted and advanced physical rehabilitation for several people who need rehabilitation services, including the population with myotonic dystrophy type 1 (DM1). The PACE tool, an innovative web tool integrating pragmatic physical activity programs, seems to be an interesting and innovative intervention to counter physical deficiencies of people with DM1, which are unfortunately accentuated by the pandemic, while reducing the risk of COVID-19 exposure. Objectives: 1) Evaluate the feasibility, usability and acceptability of the PACE tool in the DM1 population; 2) Evaluate the effects of the intervention on their physical and cognitive health; and 3) Estimate the cost-effectiveness ratio of this intervention. Method: Sixty people (experimental group = 40 and control group = 20) will participate in this randomized intervention study. Participants in the experimental group will be assigned to one of the 35 physical activity programs adapted to their condition of the PACE tool. The program must be performed on a daily basis for a period of 12 weeks. Physical and cognitive health will be assessed before and after the remote intervention via ZOOM, for all participants.

Conditions

Interventions

TypeNameDescription
OTHERRemote activity programParticipant will have to do exercise at home everyday (15min/day)

Timeline

Start date
2021-08-11
Primary completion
2025-12-31
Completion
2026-12-01
First posted
2021-10-08
Last updated
2025-03-28

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT05072288. Inclusion in this directory is not an endorsement.